Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.

ABSTRACT:

Background

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and has a median survival after diagnosis of 2-5 years. Pirfenidone is the first approved antifibrotic drug for the treatment of IPF. Here we report the functional progress, side effects and survival data of a population of patients with IPF, diagnosed at our centre and treated with pirfenidone.

Methods

We enrolled 91 patients with IPF (71 males) treated with pirfenidone. Clinical, survival and functional details were collected retrospectively at start of therapy and after 12, 24, 36 and 48 months of treatment. Lung function tests at least 12 months before starting therapy were available for 40 patients and were entered in the database, as well as side effects.

Results

SUBMITTER: Vietri L 

PROVIDER: S-EPMC7029533 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature